Multi-dimensional image reconstruction and analysis for expert-system diagnosis
An electronic storage medium that comprises at least one radiopharmaceutical identity, SPECT measured values of at least one radiopharmaceutical kinetic parameter of a flow rate across a tissue membrane, for the radiopharmaceutical, and a set of instructions for associating the at least one radiopharmaceutical kinetic parameter with a disease signature.
1. A non-transitory tangible medium comprising
at least one radiopharmaceutical identity;
SPECT measured values of at least one radiopharmaceutical kinetic parameter of a flow rate across a tissue membrane, for the radiopharmaceutical, and
a set of instructions for associating the at least one radiopharmaceutical kinetic parameter with a disease signature.
2. The non-transitory tangible medium of claim 1 , wherein the disease signature is indicative of perfusion.
3. The non-transitory tangible medium of claim 1 , the disease signature is indicative of blood flow quality.
4. The non-transitory tangible medium of claim 1 , wherein the disease signature is indicative of a metabolic rate.
5. Apparatus for performing automatic diagnosis, based on SPECT data, comprising at least one computer usable non-transitory tangible medium having a computer readable program code embodied therein, said computer readable program code adapted to be executed to implement a set of instructions for:
providing pathological signatures, each characterized by a unique combination of at least two patient parameters, at least one of which relating to behavior of a radiopharmaceutical in vivo, as measured by SPECT;
measuring the at least two patient parameters, wherein the at least one patient parameter relating to the behavior of the radiopharmaceutical in vivo is measured by SPECT imaging; and
automatically diagnosing a pathology by automatically matching the at least two patient parameters and the pathological signatures.
6. The apparatus of claim 5 , wherein automatically diagnosing a pathology comprises automatically diagnosing based on a database of values for normal and diseased populations.
7. The apparatus of claim 6 , wherein automatically diagnosing includes determining a degree of a pathology.
8. The apparatus of claim 5 , wherein measuring includes measuring at least one radiopharmaceutical kinetic parameter of a flow rate across a tissue membrane.
9. The apparatus of claim 5 , wherein the set of instructions further comprises determining a preferred administration dose of a pharmaceutical agent for at least one future administration to the body according to the pathology.
10. The apparatus of claim 9 , wherein the future administration is of a radiopharmaceutical agent.
11. The method of claim 9 , wherein the future administration is of a therapeutic agent.
12. The apparatus of claim 9 , wherein the future administration takes into account a member of a group consisting of: toxicity, radiation dose, clearance rate, uptake rate by an organ, and a measurement provided by a previous administration to weigh benefit and potential harm.
13. The apparatus of claim 5 , wherein at least one of the pathological signatures is indicative of perfusion.
14. The apparatus of claim 5 , wherein at least one of the pathological signatures is indicative of blood flow quality.
15. The apparatus of claim 5 , wherein at least one of the pathological signatures is indicative of a metabolic rate.
16. A non-transitory tangible medium comprising a set of instructions for:
providing pathological signatures, each characterized by a unique combination of at least two patient parameters, at least one of which relating to behavior of a radiopharmaceutical in vivo, as measured by SPECT;
measuring the at least two patient parameters, wherein the at least one patient parameter relating to the behavior of the radiopharmaceutical in vivo is measured by SPECT imaging; and
automatically diagnosing a pathology by automatically matching the at least two patient parameters and the pathological signatures.
17. The non-transitory tangible medium of claim 16 , wherein automatically diagnosing a pathology comprises automatically diagnosing based on a database of values for normal and diseased populations.
18. The non-transitory tangible medium of claim 16 , wherein measuring includes measuring at least one radiopharmaceutical kinetic parameter of a flow rate across a tissue membrane.
19. The apparatus of claim 16 , wherein the automatically diagnosing further comprises automatically determining the degree of the pathology.
20. The non-transitory tangible medium of claim 16 , wherein the at least two patient parameters comprises a distribution of the radiopharmaceutical in the body.
21. The non-transitory tangible medium of claim 16 , wherein at least one of the at least two patient parameters is relating to a combination of at least two radiopharmaceuticals.
22. The non-transitory tangible medium of claim 16 , wherein at least one of the at least two patient parameters is relating to a combination of at least two radiopharmaceuticals.